WuXi Biologics (Cayman) 過去の業績

過去基準チェック /26

WuXi Biologics (Cayman)は、平均年間23.7%の収益成長を遂げていますが、 Life Sciences業界の収益は、年間成長しています。収益は、平均年間11.7% 32.7%収益成長率で成長しています。 WuXi Biologics (Cayman)の自己資本利益率は6.7%であり、純利益率は15.4%です。

主要情報

23.7%

収益成長率

22.3%

EPS成長率

Life Sciences 業界の成長	21.5%
収益成長率	32.7%
株主資本利益率	6.7%
ネット・マージン	15.4%
前回の決算情報	30 Jun 2024

Recent updates

収支内訳

WuXi Biologics (Cayman) の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

OTCPK:WXXW.Y 収益、費用、利益 ( )CNY Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 24	17,116	2,632	2,356	788
31 Mar 24	17,075	3,016	2,221	787
31 Dec 23	17,034	3,400	2,086	786
30 Sep 23	16,794	3,776	2,021	769
30 Jun 23	16,554	4,152	1,956	753
31 Mar 23	15,911	4,286	1,824	718
31 Dec 22	15,269	4,420	1,693	683
30 Sep 22	14,179	4,251	1,472	670
30 Jun 22	13,090	4,081	1,251	657
31 Mar 22	11,690	3,735	1,192	579
31 Dec 21	10,290	3,388	1,133	502
30 Sep 21	9,183	3,092	1,043	398
30 Jun 21	8,075	2,795	952	295
31 Mar 21	6,844	2,242	837	299
31 Dec 20	5,612	1,689	722	304
30 Sep 20	4,967	1,494	648	289
30 Jun 20	4,321	1,300	574	275
31 Mar 20	4,152	1,157	512	267
31 Dec 19	3,984	1,014	451	260
30 Sep 19	3,535	922	427	241
30 Jun 19	3,087	831	404	222
31 Mar 19	2,811	731	365	196
31 Dec 18	2,534	631	326	169
30 Sep 18	2,277	520	270	132
30 Jun 18	2,019	410	214	94
31 Mar 18	1,819	331	195	84
31 Dec 17	1,619	253	175	74
30 Sep 17	1,429	177	155	66
30 Jun 17	1,233	149	128	60
31 Mar 17	1,111	145	119	56
31 Dec 16	989	141	110	53
30 Sep 16	889	171	101	61
31 Dec 15	557	45	86	40
31 Dec 14	332	42	48	35

質の高い収益: WXXW.Yは高品質の収益を持っています。

利益率の向上: WXXW.Yの現在の純利益率 (15.4%)は、昨年(25.1%)よりも低くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: WXXW.Yの収益は過去 5 年間で年間23.7%増加しました。

成長の加速: WXXW.Yは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: WXXW.Yは過去 1 年間で収益成長率がマイナス ( -36.6% ) となったため、 Life Sciences業界平均 ( -4.7% ) と比較することが困難です。

株主資本利益率

高いROE: WXXW.Yの自己資本利益率 ( 6.7% ) は低いとみなされます。

WuXi Biologics (Cayman) 過去の業績

過去 基準チェック /26

主要情報

最近の業績更新

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

Recent updates

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021

WuXi Biologics Announces Completion of GMP Production At 24,000L Line of Its Drug Substance Facility MFG5

WuXi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed to acquire a 90% stake in CMAB Biopharma Inc. from CBC Group.

WuXi Biologics (Cayman) Inc. (SEHK:2269) entered into an equity agreement to acquire Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

Exelixis, Inc. Enters into License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline

Wuxi Biologics (Cayman) Inc. Receives Remote Pre-Approval Inspection by European Medicines Agency on MFG4 Facility

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

Antengene Corporation Limited Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage

Oxford BioTherapeutics Ltd Designates Second Bispecific Antibody Program Leveraging Wuxi Biologics’ Wuxibody® Platform

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform

WuXi Biologics Receives GMP Certification from Brazil's ANVISA

WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed into an Asset Purchase Agreement to acquire Drug Substance Facility in Wuppertal from Bayer Aktiengesellschaft (XTRA:BAYN) for € 110 million.

Arcus Biosciences, Inc. Expands Strategic Relationship with WuXi Biologics to Develop a Best-in-Class anti-CD39 Antibody for the Treatment of Cancer

AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development

WuXi Biologics and AB2 Bio Ltd. Announces Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa

Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines

WuXi Biologics (Cayman) Inc. has completed a Follow-on Equity Offering in the amount of HKD 6.165 billion.

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /26